Checkpoint blockade drugs such as Yervoy, Opdivo and Keytruda have created a lot of excitement as they have been shown to unleash a tumor destructive immune response and long term remissions in some patients.

However, these drugs work only in a small percentage of patients with only a few types of tumors. Much research is now devoted to discovering ways to increase the applicability of these drugs.

Recently it was found that checkpoint drugs work best in highly mutated tumors that are highly infiltrated with immune cells, known as "HOT" tumors. Unfortunately, the overwhelming majority of human tumors are "COLD" tumors, without immune cells.


Immunovative scientists have preliminary evidence that suggests that Mirror Effect products work by converting a COLD tumor to a HOT tumor.


Current clinical trials are now designed to explore and prove this concept. All patients. In our clinical trials will be monitored for amount and type of immune cell infiltration. We will be able to determine how the amounts and types of immune cells in the tumor change over time. Comparing this information with data on the respond of patients to our immunotherapy is another powerful tool available for optimizing our products to elicit the most effective types of immune responses.




Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals

Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more